Chosa Oncology presents Phase III SPLENDOUR data showing Platin-DRP predicts overall survival in platinum-treated NSCLC patients on NanoString platform

  • Chosa Oncology reported ASCO-presented data validating its Platin-DRP biomarker on the NanoString platform in advanced lung cancer.
  • The analysis linked the biomarker’s scores to overall survival outcomes in patients treated with platinum chemotherapy in a Phase III study.
  • The results support using Platin-DRP to identify patients more likely to benefit from platinum-based treatment.
  • NanoString compatibility is positioned as a key step to broaden clinical adoption, supporting commercial scalability for the test.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chosa Oncology AB published the original content used to generate this news brief via Cision (Ref. ID: 20260531:BIT:9578:0) on June 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.